Vanguard Investments Australia
ABUS icon

Vanguard Investments Australia’s Arbutus Biopharma ABUS Stock Holding History

Vanguard Investments Australia’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Hold
31,288
– – ﹤0.01% 2224
2026
Q1 		$141K Buy
+31,288
New +$137K ﹤0.01% 2180

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.19B AUM 63.92% 1-Year Est. Return

Vanguard Investments Australia's ABUS Position: Q2 2026 in Review

Vanguard Investments Australia held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 31,288 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #2224.

Vanguard Investments Australia first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Vanguard Investments Australia held 31,288 shares of Arbutus Biopharma worth $150K as of Q2 2026.
  • Vanguard Investments Australia left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2224 holding.
  • Vanguard Investments Australia first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.